阿托伐他汀对2型糖尿病血栓前状态的影响

The clinical intervention of atorvastatin in type 2 diabetes with prothrombotic state

目的观察阿托伐他汀对2型糖尿病血栓前状态的影响。方法糖尿病患者62例,有血栓前状态分子标志物异常,分成2组。治疗组在常规治疗的基础上口服阿托伐他汀10mg,每日1次。对照组用常规2型糖尿病治疗。4周后监测患者的血栓前状态分子标志物冯·威利布兰德因子抗原(von Willebrand factor antigen,vWFAg)、血小板!颗粒膜蛋白(platetet alphagranule membrane protein-140,GMP-140)、D-二聚体(D-dimer)、Ⅰ型纤溶酶原激活物抑制因子(activatorof plasminogen;plasminogen activator,PAI-1)的变化,并进行疗效对比。结果治疗组患者治疗后的血栓前状态分子标志物的水平下降,差异有统计学意义(P<0.05),但是对照组血栓前状态分子标志物的水平下降差异无统计学意义。结论阿托伐他汀对2型糖尿病患者血栓前状态的干预有显著疗效。

Objectives To observe the clinical intervention of atorvastafin in type 2 diabetes with prothrombofic state. Methods 62 patients with abnormal molecular markers in prothrombofic state in diabetes were randomly divided into two groups. The treated group was given atorvastafin 10mg once daily, while control group was given traditional therapy to type 2 diabetes. The changes of molecular markers（vWFAg, GMP-140, D-dimer, PAI-1 ） in all patients have been monitored after treating for 4 weeks, and then the effects of therapy in two groups were compared. Results The molecular markers levels between before and after 4 weeks treatment in the treated group had statistical differences （P〈0.05）, and in the control group the molecular marker levels had no statistical differences （P 〉0.05）. Conclusions The intervention of atorvastatin in prothrombotic state in type 2 diabetes has obtained obvious effect of therapy.